Last update: July 31, 2018
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
Spirapril and its active metabolite spiraprilat are angiotensin converting enzyme inhibitors (ACEI) used in the treatment of hypertension.
Oral administration once day.
Since the last update we have not found published data on its excretion in breastmilk.
Other compounds from the same group (ACEI) are not excreted in breastmilk in significant amounts, but until there is more information about this drug in relation to breastfeeding, safer known alternatives are preferable (Anderson 2018).
Due to its possible renal toxicity in preterm infants, it is preferable to avoid its use during the neonatal period in case of prematurity. (Serrano 2015).
The protective role of breastfeeding against maternal hypertension has been proven (Park 2018).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) from Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM